How can we help?
How will the new reimbursement chapter and companioning legislative amendments about personalized medicines and their markers affect the reimbursement of our product?
Does our health economic model meet the methodological Belgian recommendations? and how to implement our health economic model in the Belgian context?
How can the new legislation be translated to a pragmatic approach?
What is the optimal path for reimbursement?
How to write the pricing & reimbursement dossier? We need support with submission of our pricing & reimbursement dossier in Belgium.
Is there an opportunity for an early access program to medicines in Belgium?
What are the key factors determining the reimbursement for our drug in Belgium?
We need help with our systematic literature review
Why do we need to pay certain taxes for our product to the Belgian government (NIHDI/FAMHP)?
What are the most important rules to know about the complex market access legal system in Belgium?
Go to home
Scroll to top